Filed by Revance Therapeutics, Inc.
Pursuant to Rule 425 under the Securities Act of 1933, as amended
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934, as amended
Subject Company: Hint, Inc.
(Commission File No. 001-36297)
The following communication is being filed in connection with the acquisition of Hint, Inc. by Revance Therapeutics, Inc.
RVNC HintMD Announcement
Revance Corporate Social Channels Content
Instagram:
|
|
|
Today we announced an agreement to acquire @hintmd and its proprietary fintech platform for aesthetic practices.
HintMD provides a seamless, simple, and smart payment solution that transforms the existing ecosystem, improving aesthetic practice economics and patient experience. Visit our website to learn more, and see link in bio for important additional
information. #Revance #DaringToMakeADifference #HintMD #Aesthetics
|
|
|
|
Graphic asset: Instagram row take-over featuring 3 images: Quote card, logo lock-up, and an image of the POS.
Mark Foley quote:
|
|
|
|
The strategic acquisition of HintMD would augment Revances strong aesthetics product portfolio with
an innovative fintech platform to transform both the practice and patient experience and deliver real value.
|
Twitter:
|
|
|
Today we announced an agreement to Acquire @HintMD and its proprietary fintech platform for aesthetic practices.
Learn more: [link to press release] Important additional information is provided at the following link: [link to legal page] #Revance #HintMD #Aesthetics
|
|
|
|
Graphic asset: Mark Foley quote card:
|
|
|
|
The strategic acquisition of HintMD would augment Revances strong aesthetics product portfolio with
an innovative fintech platform to transform both the practice and patient experience and deliver real value.
|
Mark J. Foley, President & Chief Executive Officer of Revance Therapeutics
Facebook, LinkedIn:
|
|
|
Today we announced an agreement to acquire HintMD and its proprietary fintech platform for aesthetic practices.
HintMD provides a seamless, simple, and smart payment solution that transforms the existing ecosystem, improving aesthetic practice economics and patient experience. Learn more: [link to press release] #Revance #DaringToMakeADifference #HintMD
#Aesthetics Important additional information is provided at the following link: [link to legal page]
|
|
|
|
Graphic asset: Mark Foley quote card:
|
|
|
|
The strategic acquisition of HintMD would augment Revances strong aesthetics product portfolio with
an innovative fintech platform to transform both the practice and patient experience and deliver real value.
|
Mark J. Foley, President & Chief Executive Officer of Revance Therapeutics
Additional Information and Where to Find It
Revance
plans to file with the SEC, and the parties plan to furnish to the investors of HintMD, a Registration Statement on Form S-4, which will constitute a prospectus of Revance and will include an information
statement of HintMD, in connection with the proposed transaction. The prospectus/information statement described above will contain important information about Revance, HintMD, the proposed transaction and related matters. Investors are urged to
read the prospectus/information statement carefully when it becomes available. Investors will be able to obtain free copies of these documents, and other documents filed with the SEC by Revance, through the website maintained by the SEC at
www.sec.gov. In addition, investors will be able to obtain free copies of these documents from Revance by going to the Revance Investor Relations web page at https://investors.revance.com/ and clicking on the link titled
Financials and Filings or by contacting Revances Investor Relations group at the following:
Revance Therapeutics, Inc.: Jeanie Herbert,
714-325-3584, jherbert@revance.com or Gilmartin Group, LLC: Laurence Watts,
619-916-7620, laurence@gilmartinir.com